Browse > Article
http://dx.doi.org/10.4142/jvs.2018.19.6.788

Synergistic effect of ribavirin and vaccine for protection during early infection stage of foot-and-mouth disease  

Choi, Joo-Hyung (Animal and Plant Quarantine Agency)
Jeong, Kwiwan (Bio-Center, Gyeonggi Business & Science Accelerator)
Kim, Su-Mi (Animal and Plant Quarantine Agency)
Ko, Mi-Kyeong (Animal and Plant Quarantine Agency)
You, Su-Hwa (Animal and Plant Quarantine Agency)
Lyoo, Young S. (College of Veterinary Medicine, Konkuk University)
Kim, Byounghan (Animal and Plant Quarantine Agency)
Ku, Jin-Mo (Bio-Center, Gyeonggi Business & Science Accelerator)
Park, Jong-Hyeon (Animal and Plant Quarantine Agency)
Publication Information
Journal of Veterinary Science / v.19, no.6, 2018 , pp. 788-797 More about this Journal
Abstract
In many countries, vaccines are used for the prevention of foot-and-mouth disease (FMD). However, because there is no protection against FMD immediately after vaccination, research and development on antiviral agents is being conducted to induce protection until immunological competence is produced. This study tested whether well-known chemicals used as RNA virus treatment agents had inhibitory effects on FMD viruses (FMDVs) and demonstrated that ribavirin showed antiviral effects against FMDV in vitro/in vivo. In addition, it was observed that combining the administration of the antiviral agents orally and complementary therapy with vaccines synergistically enhanced antiviral activity and preserved the survival rate and body weight in the experimental animals. Antiviral agents mixed with an adjuvant were inoculated intramuscularly along with the vaccines, thereby inhibiting virus replication after injection and verifying that it was possible to induce early protection against viral infection prior to immunity being achieved through the vaccine. Finally, pigs treated with antiviral agents and vaccines showed no clinical signs and had low virus excretion. Based on these results, it is expected that this combined approach could be a therapeutic and preventive treatment for early protection against FMD.
Keywords
foot-and-mouth disease; ribavirin; vaccine;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Chen W, Liu M, Jiao Y, Yan W, Wei X, Chen J, Fei L, Liu Y, Zuo X, Yang F, Lu Y, Zheng Z. Adenovirus-mediated RNA interference against foot-and-mouth disease virus infection both in vitro and in vivo. J Virol 2006, 80, 3559-3566.   DOI
2 Chinsangaram J, Moraes MP, Koster M, Grubman MJ. Novel viral disease control strategy: adenovirus expressing alpha interferon rapidly protects swine from foot-and-mouth disease. J Virol 2003, 77, 1621-1625.   DOI
3 Connor E, Morrison S, Lane J, Oleske J, Sonke RL, Connor J. Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection. Antimicrob Agents Chemother 1993, 37, 532-539.   DOI
4 de Avila Botton S, Brum MC, Bautista E, Koster M, Weiblen R, Golde WT, Grubman MJ. Immunopotentiation of a foot-and-mouth disease virus subunit vaccine by interferon alpha. Vaccine 2006, 24, 3446-3456.   DOI
5 Durk RC, Singh K, Cornelison CA, Rai DK, Matzek KB, Leslie MD, Schafer E, Marchand B, Adedeji A, Michailidis E, Dorst CA, Moran J, Pautler C, Rodriguez LL, McIntosh MA, Rieder E, Sarafianos SG. Inhibitors of foot and mouth disease virus targeting a novel pocket of the RNA-dependent RNA polymerase. PLoS One 2010, 5, e15049.   DOI
6 Golde WT, Pacheco JM, Duque H, Doel T, Penfold B, Ferman GS, Gregg DR, Rodriguez LL. Vaccination against foot-and-mouth disease virus confers complete clinical protection in 7 days and partial protection in 4 days: use in emergency outbreak response. Vaccine 2005, 23, 5775-5782.   DOI
7 Gonzalez-Peralta RP, Kelly DA, Haber B, Molleston J, Murray KF, Jonas MM, Shelton M, Mieli-Vergani G, Lurie Y, Martin S, Lang T, Baczkowski A, Geffner M, Gupta S, Laughlin M; International Pediatric Hepatitis C Therapy Group. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology 2005, 42, 1010-1018.   DOI
8 Kamstrup S, Frimann TH, Barfoed AM. Protection of Balb/c mice against infection with FMDV by immunostimulation with CpG oligonucleotides. Antiviral Res 2006, 72, 42-48.   DOI
9 Kim SM, Kim SK, Park JH, Lee KN, Ko YJ, Lee HS, Seo MG, Shin YK, Kim B. A recombinant adenovirus bicistronically expressing porcine interferon-${\alpha}$ and interferon-$\gamma$ enhances antiviral effects against foot-and-mouth disease virus. Antiviral Res 2014, 104, 52-58.   DOI
10 Kim SM, Park JH, Lee KN, Kim SK, You SH, Kim T, Tark D, Lee HS, Seo MG, Kim B. Robust protection against highly virulent foot-and-mouth disease virus in swine by combination treatment with recombinant adenoviruses expressing porcine alpha and gamma interferons and multiple small interfering RNAs. J Virol 2015, 89, 8267-8279.   DOI
11 Knowles NJ, Samuel AR. Molecular epidemiology of foot-and-mouth disease virus. Virus Res 2003, 91, 65-80.   DOI
12 Lee DU, Je SH, Yoo SJ, Kwon T, Shin JY, Byun JJ, Park JH, Jeong KW, Ku JM, Lyoo YS. Hematological adverse effects and pharmacokinetics of ribavirin in pigs following intramuscular administration. J Vet Pharmacol Ther 2017, 40, 561-568.   DOI
13 Lertora JJ, Rege AB, Lacour JT, Ferencz N, George WJ, VanDyke RB, Agrawal KC, Hyslop NE Jr. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1991, 50, 442-449.   DOI
14 Moraes MP, Chinsangaram J, Brum MC, Grubman MJ. Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine. Vaccine 2003, 22, 268-279.   DOI
15 Park JN, Ko MK, Kim RH, Park ME, Lee SY, Yoon JE, Choi JH, You SH, Park JW, Lee KN, Chun JE, Kim SM, Tark D, Lee HS, Ko YJ, Kim B, Lee MH, Park JH. Construction of stabilized and tagged foot-and-mouth disease virus. J Virol Methods 2016, 237, 187-191.   DOI
16 Grubman MJ. Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals. Biologicals 2005, 33, 227-234.   DOI
17 Moraes MP, de Los Santos T, Koster M, Turecek T, Wang H, Andreyev VG, Grubman MJ. Enhanced antiviral activity against foot-and-mouth disease virus by a combination of type I and II porcine interferons. J Virol 2007, 81, 7124-7135.   DOI
18 Mort M, Convey I, Baxter J, Bailey C. Animal disease and human trauma: the psychosocial implications of the 2001 UK foot and mouth disease disaster. J Appl Anim Welf Sci 2008, 11, 133-148.   DOI
19 Nettleton PF, Davies MJ, Rweyemamu MM. Guanidine and heat sensitivity of foot-and-mouth disease virus (FMDV) strains. J Hyg (Lond) 1982, 89, 129-138.   DOI
20 Paarlberg PL, Lee JG, Seitzinger AH. Potential revenue impact of an outbreak of foot-and-mouth disease in the United States. J Am Vet Med Assoc 2002, 220, 988-992.   DOI
21 Perales C, Agudo R, Domingo E. Counteracting quasispecies adaptability: extinction of a ribavirin-resistant virus mutant by an alternative mutagenic treatment. PLoS One 2009, 4, e5554.   DOI
22 Alexandersen S, Zhang Z, Donaldson AI, Garland AJ. The pathogenesis and diagnosis of foot-and-mouth disease. J Comp Pathol 2003, 129, 1-36.   DOI
23 Quan M, Murphy CM, Zhang Z, Alexandersen S. Determinants of early foot-and-mouth disease virus dynamics in pigs. J Comp Pathol 2004, 131, 294-307.   DOI
24 Rada B, Dragun M. Antiviral action and selectivity of 6-azauridine. Ann N Y Acad Sci 1977, 284, 410-417.   DOI
25 Richmond JY, Hamilton LD. Foot-and-mouth disease virus inhibition induced in mice by synthetic double-stranded RNA (polyriboinosinic and polyribocytidylic acids). Proc Natl Acad Sci U S A 1969, 64, 81-86.   DOI
26 Airaksinen A, Pariente N, Menendez-Arias L, Domingo E. Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology 2003, 311, 339-349.   DOI
27 Alexandersen S, Donaldson AI. Further studies to quantify the dose of natural aerosols of foot-and-mouth disease virus for pigs. Epidemiol Infect 2002, 128, 313-323.   DOI
28 Belsham GJ. Distinctive features of foot-and-mouth disease virus, a member of the picornavirus family; aspects of virus protein synthesis, protein processing and structure. Prog Biophys Mol Biol 1993, 60, 241-260.   DOI
29 Salazar M, Yun NE, Poussard AL, Smith JN, Smith JK, Kolokoltsova OA, Patterson MJ, Linde J, Paessler S. Effect of ribavirin on junin virus infection in guinea pigs. Zoonoses Public Health 2012, 59, 278-285.   DOI
30 Sainz B Jr, Halford WP. Alpha/Beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1. J Virol 2002, 76, 11541-11550.   DOI
31 Vollmer J. Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9. Expert Opin Biol Ther 2005, 5, 673-682.   DOI
32 Vollstedt S, Arnold S, Schwerdel C, Franchini M, Alber G, Di Santo JP, Ackermann M, Suter M. Interplay between alpha/beta and gamma interferons with B, T, and natural killer cells in the defense against herpes simplex virus type 1. J Virol 2004, 78, 3846-3850.   DOI
33 Zeng J, Wang H, Xie X, Li C, Zhou G, Yang D, Yu L. Ribavirin-resistant variants of foot-and-mouth disease virus: the effect of restricted quasispecies diversity on viral virulence. J Virol 2014, 88, 4008-4020.   DOI